-+ 0.00%
-+ 0.00%
-+ 0.00%

Samsung Biopharmaceuticals Holdings Co., Ltd.: The subsidiary Samsung Biopharmaceuticals signed an exclusive supply agreement under the Brazilian government's rare disease treatment program to supply SB12, a biosimilar of eculimab.

Zhitongcaijing·10/21/2026 01:57:13
Listen to the news
Samsung Biopharmaceuticals Holdings Co., Ltd.: The subsidiary Samsung Biopharmaceuticals signed an exclusive supply agreement under the Brazilian government's rare disease treatment program to supply SB12, a biosimilar of eculimab.